Procedure: Women diagnosed with Polycystic Ovary Syndrome will be assessed using a screening performa. Women who met the inclusion criteria and gave their consent to participate in the study protocol will be recruited. Women will then be randomly assigned to the four groups using computerized randomization technique.

Pre and post assessment will be performed for the following variables.

Menstrual Regularity: Assessed at baseline and at post-treatment follow-up. Participants will self-monitor their menstrual cycles using a standardized menstrual diary throughout the study period. Regularity will be defined as cycles occurring every 21–35 days over at least two consecutive months.

 Menstrual Pain: Measured using the Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).VAS scores will be recorded pre-intervention and post-intervention. Menstrual regularity: will measure at initial presentation and post treatment follow up. Menstrual cycle will self-monitored by subjects using a standardized menstrual diary.

Body Mass Index (BMI): BMI is calculated as: the ratio of body weight in kilograms to the square of the height in meters where in height will measure to 0.5cm using calibrated stadiometer and body weight will measure using calibrated clinical scale to the nearest 0.01 kg. Measurements will be taken with participants wearing light clothing and no shoes.

Fertility Parameters: Anti-Müllerian Hormone (AMH) levels will be used as a marker of ovarian reserve. Blood samples for AMH testing will be collected pre- and post-intervention under standardized conditions.

Quality of life: Evaluated using standardized tools: Depression, Anxiety and Stress Scale – 21 (DASS-21), Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ).